Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2025-06 · 52 (7) · 2431-2443
DOI: 10.1007/s00259-025-07102-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 03.02.2025. Verfasst von Philipp Ritt und 11 weiteren Autor:innen. Beteiligte Einrichtung: ITM Oncologics GmbH, Lichtenbergstrasse 1, 85748, Garching, Munich, Germany. philipp.ritt@itm-radiopharma.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Radiopharmaceuticals, Heterocyclic Compounds, 1-Ring. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ICPO, ETH MedLab Fellowship, SNSF.
Abstract (Originalsprache)
PURPOSE: Several prostate-specific membrane antigen (PSMA) radiopharmaceuticals have been used for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). In an attempt to improve the tumour accumulation, new PSMA ligands were developed with an albumin-binding entity to enhance the blood circulation and, hence, tumour accumulation. In preclinical studies, [177Lu]Lu-SibuDAB, a radiopharmaceutical with moderate albumin-binding properties, outperformed [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T. The aim of this study was to evaluate the dosimetry of [177Lu]Lu-SibuDAB in patients diagnosed mCRPC. METHODS: Seventeen patients (median age 72 years, range 63‒83) diagnosed with progressive disease of mCRPC were included in this prospective study after exhausting all available treatment options. They were injected with 5.3 ± 0.5 GBq (mean ± standard deviation) [177Lu]Lu-SibuDAB as a first treatment cycle. Sixteen of these patients underwent sequential whole-body SPECT/CT and activity determination in venous blood samples for dosimetry purposes. Absorbed doses to the salivary glands, liver, spleen, kidneys, and red marrow as well as selected tumour lesions were calculated in OLINDA/EXM™ and compared to published values for previously established PSMA radiopharmaceuticals. RESULTS: Absorbed dose coefficients (ADC) to tumours (9.9 ± 5.4 Gy/GBq) were about 2-fold higher than those reported for clinically approved PSMA radiopharmaceuticals. ADC to salivary glands, liver, spleen, kidneys and red marrow were higher (0.5 ± 0.2, 0.2 ± 0.05, 0.2 ± 0.1, 1.8 ± 0.6, 0.1 ± 0.04 Gy/GBq, respectively) than for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T, but lower than for [177Lu]Lu-PSMA-ALB-56, a previously investigated long-circulating PSMA radiopharmaceutical. The tumour-to-kidneys, tumour-to-red marrow, tumour-to-salivary glands ADC ratio were 6.6, 102, 33.1. These ratios were comparable to those of [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T for kidneys and red-marrow, but higher for salivary glands. CONCLUSION: [177Lu]Lu-SibuDAB showed a prolonged blood circulation time and, hence, a significantly increased absorbed tumour dose, while tumour-to-organ ADC ratios were similar to conventional PSMA radiopharmaceuticals. Further clinical investigations to evaluate the efficacy and safety of [177Lu]Lu-SibuDAB are, thus, warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ITM Oncologics GmbH, Lichtenbergstrasse 1, 85748, Garching, Munich, Germany. philipp.ritt@itm-radiopharma.com.
- Chair for Clinical Nuclear Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany. philipp.ritt@itm-radiopharma.com.
- Center for Nuclear Medicine & PET/CT Positronmed, 7501068, Providencia, Santiago, Chile.
- Facultad de Medicina Veterinaria y Agronomía, Instituto de Ciencias Naturales, Universidad de las Américas, Santiago, Chile.
- Departamento de Urología, Hospital Clínico San Borja Arriarán, Universidad de Chile, Santiago, Chile.
- Positronpharma SA, 7501068, Providencia, Santiago, Chile.
Förderung
- ICPO
- ETH MedLab Fellowship
- SNSF
- Horizon 2020 EU
Zitieren
APA
Ritt, P., Fernández, R., Soza-Ried, C., Nicolai, H., Amaral, H., Krieger, K., Mapanao, A. K., Rotger, A., Zhernosekov, K., Schibli, R., Müller, C., & Kramer, V. (2025). Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 52(7), 2431-2443. https://doi.org/10.1007/s00259-025-07102-8
Vancouver
Ritt P, Fernández R, Soza-Ried C, Nicolai H, Amaral H, Krieger K, et al. Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(7):2431-2443. doi:10.1007/s00259-025-07102-8
BibTeX
@article{Ritt2025,
author = {Ritt, Philipp and Fernández, René and Soza-Ried, Cristian and Nicolai, Heinz and Amaral, Horacio and Krieger, Korbinian and Mapanao, Ana Katrina and Rotger, Amanda and Zhernosekov, Konstantin and Schibli, Roger and Müller, Cristina and Kramer, Vasko},
title = {Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {7},
pages = {2431--2443},
doi = {10.1007/s00259-025-07102-8}
}
EUVIMED